General Daraxonrasib shows durable responses in RAS-mutant lung cancerBy Healthcare Propulsion StaffSeptember 2, 20260 Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in…
